Merck? Check. Roche? Check. Now Bristol Myers Squibb wants AstraZeneca to pay for PD-L1 patents
Having settled patent lawsuits with Merck and Roche over their PD-(L)1 drugs, Bristol Myers Squibb has found a new target in its crusade to protect …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
